Todd Carter, PhD (CSO at Voyager Therapeutics) talks with incoming Communications Committee Chair Lynnea Olivarez about changes in the approach to developing gene therapies for CNS disorders like Huntington's disease.Show your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

ASGCT Board of Directors member Lindsey George, MD, (Children's Hospital of Philadelphia) discusses the dramatic advancements in available treatment options for patients with hemophilia and the responsibility of scientists and clinicians in guiding patients through these once-in-a-lifetime decisions. Host: Lynnea Olivarez, incoming chair of the ASGCT Communications CommitteeShow your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

Incoming ASGCT Communications Committee chair Lynnea Olivarez catches up with ASGCT Career Development Award winner Ashley Cooney, PhD, (University of Iowa) to discuss her work in vector-delivered airway gene transfer and use of saline solution to "dramatically increase" gene transfer.Show your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

Leah Myers, Executive Director of the FamilieSCN2A Foundation, and Jenny Burke, who sits on the organization's board, talk about the importance of empowering patients and families affected by genetic diseases. Host: Lynnea OlivarezShow your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

Dr. Charles Murry, a medical doctor and leading researcher in stem cell therapy and organ regeneration, shares insights from his groundbreaking work on reprogramming injured heart cells. He envisions a future where organ regeneration could revolutionize treatments for heart failure and kidney disease. Dr. Murry discusses the shift from industry to academia in cell therapy, emphasizing the need for collaboration in research. Tune in to explore his exciting vision for the next decade in expanding stem cell therapies.

"Storytelling is completely underrated in science," says Benjamin McLeod, a lab scientist-turned-communicator. Listen to him talk about the importance of presenting CGT research in a narrative format. Host: Lynnea OlivarezShow your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

David Segal, PhD, an abstract session co-chair at the ASGCT Annual Meeting, sheds light on groundbreaking advancements in gene targeting and correction. He discusses the transition of academic innovations like CRISPR from labs to industry, aiming to benefit rare disease patients. Segal highlights the growing influence of biotech in genetic therapies and the crucial challenges of effective delivery systems. The conversation also addresses the FDA's impactful approval of the first gene editing therapy, signaling exciting times ahead for genetic medicine.

ASGCT President Dr. Jeff Chamberlain cuts the ribbon at the ASGCT 27th Annual Meeting and, having planned much of this year's event, reflects on nearly three decades of ASGCT. Host: Lynnea Olivarez, ASGCT Communications CommitteeShow your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

Lynnea Olivarez, incoming ASGCT Communications Committee chair, will be live at the ASGCT 27th Annual Meeting talking to Society leaders, speakers, and abstract presenters about their contributions and what they're excited about at the Annual Meeting. These bite-sized pods are perfect for your walk between the hotel and convention center or your commute to work during the Annual Meeting.Show your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

Join host Chris Leidli as he sits down with Emily Walsh Martin, PhD, and Lynnea Olivarez to preview the most intriguing and promising abstracts presented at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting in Los Angeles. Emily and Lynnea share their thoughts on the breathtaking Presidential Symposium before discussing the rest of the program, including clinical implications, the potential impact on rare diseases, and more! Looking for a curated guide through the Annual Meeting? Check out ASGCT's new Session Paths! These six staff-crafted programs provide pathways for some of the most common Annual Meeting attendee profiles: First-time Attendees Cancer Clinical Science Gene Editing Regulatory + Government Affairs Viral Vectors There's still time to register! Join us at the Annual Meeting in Baltimore or from the comfort of your own home with hybrid registration options! Visit https://annualmeeting.asgct.org/register to learn more and register today.Show your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.